Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Sciences Inc.

www.gilead.com

Latest From Gilead Sciences Inc.

NIH/Industry Oncology Partnership Aims For Immunotherapy Biomarkers

The US National Institutes of Health will team up with 11 different drug-makers to explore new biomarkers with a vision of precision oncology medicine.

Research & Development Personalized Medicine

Scrip Asks… What's The Current Climate For Deal-Making? (Part 1)

Following Gilead's acquisition of Kite, buzz grew that the deal might catalyze a surge in deal-making. Scrip asked a broad cross-section of biopharma insiders and observers about the deal-making environment – first up are responses from small biotechs.

Business Strategies M & A

Pharma Q3 Results Preview: J&J, Roche Set The Scene

Most of the big pharma companies will report their third-quarter results over the next three weeks. As usual, Johnson & Johnson and Roche will get out of the blocks early on. Scrip considers what to expect from the two front-runners, in the first of our regular financial results previews.

Sales & Earnings Biosimilars

NIH/Industry Oncology Partnership Aims For Immunotherapy Biomarkers

Part of the Cancer Moonshot program, the five-year, $215 million research collaboration will be mostly funded by NIH with money from the 21st Century Cures Act.

Research & Development Cancer
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register